ICANNABINOID Trademark

Trademark Overview


On Thursday, July 19, 2018, a trademark application was filed for ICANNABINOID with the United States Patent and Trademark Office. The USPTO has given the ICANNABINOID trademark a serial number of 88045386. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Tuesday, August 25, 2020. This trademark is owned by Cannabis Science, Inc.. The ICANNABINOID trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; Pharmaceutical preparations for the treatment of inflammatory disorders; Pharmaceutical preparations for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Drug delivery agents that provide controlled release of the active ingredients for a wide variety of cannabinoid pharmaceuticals; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical agents affecting digestive organs; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical products for the prevention and treatment of cancer; Therapeutic pharmaceutical for the treatment and prevention of inflammatory bowel disease; Ph...
icannabinoid

General Information


Serial Number88045386
Word MarkICANNABINOID
Filing DateThursday, July 19, 2018
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateTuesday, August 25, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Indication of Colors claimedThe color(s) light green, green, yellow, brown, and white is/are claimed as a feature of the mark.
Disclaimer with Predetermined Text"ICANNABINOID"
Description of MarkThe mark consists of the word "ICANNABINOID" appearing with the lettering shaded in light green at the top fading to green at the bottom, appearing under a design element of an atom with a white center surrounded by yellow, light green and brown, with light green and green surrounding bands and three shaded circles with one in light green and two in green.
Goods and ServicesPharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; Pharmaceutical preparations for the treatment of inflammatory disorders; Pharmaceutical preparations for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Drug delivery agents that provide controlled release of the active ingredients for a wide variety of cannabinoid pharmaceuticals; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical agents affecting digestive organs; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical products for the prevention and treatment of cancer; Therapeutic pharmaceutical for the treatment and prevention of inflammatory bowel disease; Pharmaceutical preparations for use in gastroenterology; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Therapeutic pharmaceutical for the treatment and prevention of neurodegenerative disease; Therapeutic pharmaceutical for the treatment and prevention of neurological disorders; Pharmaceutical preparations for use in neurology; Pharmaceutical preparations and substances for the treatment and prevention of psychiatric diseases and disorders; Therapeutic pharmaceutical for the treatment and prevention of autoimmune conditions; Therapeutic pharmaceutical for the treatment and prevention of inflammation; Pharmaceutical preparations for the treatment and prevention of immune system related diseases and disorders; Therapeutic pharmaceutical for the treatment and prevention of pain; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Therapeutic pharmaceutical for the treatment of infections; Therapeutic pharmaceutical for the treatment of drug-resistant infections; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical agents affecting sensory organs; Analgesic and muscle relaxant pharmaceutical preparations; Pharmaceutical preparations for use in urology; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in opthalmology; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical products for treating respiratory diseases; Pharmaceutical preparations for skin care; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti - infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Ocular pharmaceuticals; Antibacterial pharmaceuticals; Pharmaceuticals, namely, anti-infectives

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, July 26, 2018
Primary Code005
First Use Anywhere DateMonday, January 1, 2018
First Use In Commerce DateMonday, January 1, 2018

Trademark Owner History


Party NameCannabis Science, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIrvine, CA 92612

Trademark Events


Event DateEvent Description
Tuesday, August 25, 2020ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Tuesday, August 25, 2020ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Wednesday, February 12, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, February 12, 2020NON-FINAL ACTION E-MAILED
Wednesday, February 12, 2020NON-FINAL ACTION WRITTEN
Wednesday, January 15, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, January 15, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 14, 2020ASSIGNED TO LIE
Tuesday, December 24, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, June 25, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, June 25, 2019NON-FINAL ACTION E-MAILED
Tuesday, June 25, 2019NON-FINAL ACTION WRITTEN
Thursday, June 20, 2019ASSIGNED TO EXAMINER
Tuesday, August 7, 2018ASSIGNED TO EXAMINER
Friday, July 27, 2018NOTICE OF DESIGN SEARCH CODE E-MAILED
Thursday, July 26, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM